Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Drug Information » New Medical Therapies™

Proteinuria

Patient Medical Areas

October 22, 2007

Exelixis released negative results from a phase II trial of XL784 for the treatment of proteinuria. This randomized, placebo-controlled study enrolled 130 diabetic subjects with clinically significant proteinuria. The subjects received 200 mg XL784 or placebo daily for 3 months. The primary endpoint of the trial was a significant reduction in proteinuria compared with placebo. Secondary endpoints included changes in renal function and cardiovascular events. While the treatment was determined to be safe and well tolerated, the primary endpoint was not accomplished. Exelixis plans to fully analyze the data in order to determine a future course of development for XL784.